Serine Protease HTRA1 Membranous Nephropathy With Polytypic IgG Concurrent With Plasma Cell Dyscrasia

By afschroeder • June 16, 2026

Zuckerman JE, Larson S, Abdelnour L. Serine Protease HTRA1 Membranous Nephropathy With Polytypic IgG Concurrent With Plasma Cell Dyscrasia. Kidney Med. 2026 May 12;8(7):101402. doi: 10.1016/j.xkme.2026.101402. PMID: 42290670; PMCID: PMC13254867.

Tags: Hematology/Oncology, HTRA1, IgA-lambda multiple myeloma, membranous nephropathy, Multiple myeloma, Nephrology, nephropathology, paraneoplastic membranous nephropathy, plasma cell dyscrasia HTRA1-associated membranous nephropathy, plasma cell neoplasm, polytypic IgG, progressive proteinuria, Publications, renal pathology

Favezelimab plus pembrolizumab for anti-PD-1-refractory classic Hodgkin lymphoma: an open-label phase 1/2 study

Timmerman J, Lavie D, Johnson NA, Avigdor A, Borchmann P, Andreadis C, Bazargan A, Gregory GP, Keane C, Tzoran I, Vucinic V, Zinzani PL, West[...]

A Phase 1 Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients With Advanced Gastrointestinal Cancers

Fakih M, Doi T, Tolcher A, Hong D, Tie J, Messersmith W, Koyama T, Rosen L, Borlido J, Damore MA, Delioukina M, Cheronis I, Clark[...]

Demystifying financial toxicity measures: semi-structured interviews comparing COST-FACIT and ENRICh among cancer survivors on targeted oral anticancer medications (TOAMs)

Lowenstein LM, Bernal MP, Bergren EP, Busaidy TK, Brauer ER, Ganz PA, Smith GL, Shih YT. Demystifying financial toxicity measures: semi-structured interviews comparing COST-FACIT and[...]